Inhibition of lysyl oxidase, either pharmacologically using β-aminopropionitrile monofumarate (45), or genetically by homologous recombination (38), causes aortic aneurysms, making it likely that increased Lox expression represents an adaptive mechanism that safeguards against hypertensive aneurysm progression, and the same applies to Ctgf (46). The gene discussed is LOX; the disease is aortic aneurysm.